Company news

Adial Pharmaceuticals, Inc news in 2024

Adial Pharmaceuticals, Inc's news releases, calls and decks from 2024, newest first.

View company

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

December 2, 2024

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

November 13, 2024

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

November 4, 2024

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

October 16, 2024

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

September 18, 2024

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

August 12, 2024

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

August 6, 2024

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

July 30, 2024

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

July 22, 2024

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

June 19, 2024

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

June 4, 2024

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

April 21, 2024

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

April 9, 2024

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

February 29, 2024

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

February 27, 2024

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

February 12, 2024

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

January 17, 2024

Decks in 2024